PLCB2 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q00722 |
---|---|
Clone Names | 80612096 |
Gene ID | 5330 |
---|---|
Other Names | 1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase beta-2, Phosphoinositide phospholipase C-beta-2, Phospholipase C-beta-2, PLC-beta-2, PLCB2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP9253a was selected from the N-term region of human PLCB2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PLCB2 (HGNC:9055) |
---|---|
Function | The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes (PubMed:1644792, PubMed:9188725). In neutrophils, participates in a phospholipase C-activating N-formyl peptide-activated GPCR (G protein- coupled receptor) signaling pathway by promoting RASGRP4 activation by DAG, to promote neutrophil functional responses (By similarity). |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
PLCB2 is the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes.
References
Grinberg,S., et.al, Am. J. Pathol. 175 (6), 2439-2453 (2009)Xiao,W., et.al, Cancer Cell 16 (2), 161-171 (2009)

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.